Sep 30, 2026, 11:12 AMAnalyst Ratings
Citi Says Sell Moderna After 600%-Plus Stock Gain
Citi says Moderna's revenue and profit forecasts cannot support its valuation after a 600%-plus stock gain, prompting analysts to recommend selling shares.
Listen to this briefingAudio briefing
Summary
MarketWatch reported on September 30, 2026, that Citi told investors to sell Moderna after the stock gained more than 600%. Citi analysts concluded that projected revenue and profit do not support the expectations reflected in Moderna’s share price.
The available feed provided no forecast figures, valuation metrics, time horizon, analyst names, price target, or details about Moderna’s products and pipeline. Those omissions limit assessment of Citi’s assumptions and what could change its view.
Positives
- Moderna’s stock had gained more than 600%, the only quantified performance measure in the available feed.
- The share price reflected substantial investor enthusiasm, according to Citi’s characterization of expectations embedded in the valuation.
- Citi’s assessment considered both revenue and profit forecasts, covering top-line and bottom-line expectations.
Risks & concerns
- Citi told investors to sell Moderna after the stock’s gain exceeded 600%.
- Revenue forecasts failed to justify Moderna’s share price, according to Citi analysts.
- Profit forecasts also failed to support the expectations embedded in the valuation.
- The limited feed omitted forecast values, valuation multiples, a price target, and the period covered by Citi’s analysis.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/citi-tells-investors-its-time-to-sell-moderna-after-600-plus-stock-gains-84cb9b62?mod=mw_rss_topstories
Read full article
